LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum lineNicoletta Colombo, Andrés Poveda, Ana Montes et al.|Annals of Oncology|2020Cited by 23
Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).Giovanni Scambia, Domenica Lorusso, Francesco Raspagliesi et al.|Journal of Clinical Oncology|2022Cited by 6
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With <i>BRCA</i>-Mutated and/or BRCAness Phenotype: A Randomized Phase III TrialDomenica Lorusso, Giovanni Scambia, Francesco Raspagliesi et al.|Journal of Clinical Oncology|2024Cited by 3